Ligand Pharma (LGND) Misses Q4 EPS by 45c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $255.54 +0.38%
EPS Growth %: +25.6%
Financial Fact:
Loss from operations: 5.47M
Today's EPS Names:
PLCE, COE, JVA, More
EPS Growth %: +25.6%
Financial Fact:
Loss from operations: 5.47M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $0.74, $0.45 worse than the analyst estimate of $1.19. Revenue for the quarter came in at $38.2 million versus the consensus estimate of $40.34 million.
GUIDANCE:
Ligand Pharma sees FY2017 EPS of $2.70.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- RH (RH) Tops Q1 EPS by 12c
- Oracle (ORCL) Tops Q4 EPS by 16c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
